[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-438918-105":59,"doc-detail-438918-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","tegileridine-for-moderate-to-severe-acute-pain-following-abdominal-surgery-a-randomized-double-blind-phase-3-clinical-trial","Tegileridine for moderate-to-severe acute pain following abdominal surgery - A randomized, double-blind, phase 3 clinical trial","","Phase 3 randomized, double-blind clinical trial evaluating tegileridine, a MOR-biased agonist, for moderate-to-severe acute postoperative pain after abdominal surgery. The study randomized 526 patients to placebo, tegileridine 0.75 mg, tegileridine 1.0 mg, or morphine. For effective analgesia (SPID24 at rest), tegileridine showed significantly greater pain reduction versus placebo (all p\u003C0.001) and was comparable with morphine. Total pain relief at 24 h also favored tegileridine over placebo while maintaining a comparable profile to morphine and an acceptable safety pattern.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tegileridine-for-moderate-to-severe-acute-pain-following-abdominal-surgery-a-randomized-double-blind-phase-3-clinical-trial/438918/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tegileridine-for-moderate-to-severe-acute-pain-following-abdominal-surgery-a-randomized-double-blind-phase-3-clinical-trial/438918.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What medication and target does the trial evaluate?","Question",{"text":113,"@type":114},"The trial evaluates tegileridine, a MOR-biased μ-opioid receptor agonist designed to provide analgesia with potentially fewer opioid-related adverse effects.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were patients assigned in this phase 3 study?",{"text":118,"@type":114},"A total of 526 patients with postoperative pain after abdominal surgery were randomized to placebo, tegileridine (0.75 mg or 1.0 mg), or morphine under a randomized, double-blind design.",{"name":120,"@type":111,"acceptedAnswer":121},"What did the primary outcome show compared with placebo and morphine?",{"text":122,"@type":114},"For the primary outcome of effective analgesia measured by SPID24 at rest over the first 24 hours, tegileridine produced significantly better pain reduction than placebo (all p\u003C0.001) and was comparable to morphine.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},438918,1790716434,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Article  \nTegileridine for moderate-to-severe acute pain following abdominal surgery: A randomized, doubleblind, phase 3 clinical trial  \nAuthors  \nTingting Wang, Yafeng Wang,  \nHaihui Xie, ..., Jiaqiang Zhang, Jianbo Yu, Xiangdong Chen  \nCorrespondence  \n[zhangjiq@zzu.edu.cn](zhangjiq@zzu.edu.cn) (J.Z.),  \n[yujianbo11@126.com](yujianbo11@126.com) (J.Y.),  \n[xdchen@hust.edu.cn](xdchen@hust.edu.cn) (X.C.)  \nIn brief  \nWang et al. demonstrate the clinical efficacy of tegileridine, an MOR-biased agonist, which is comparable to morphine. They provide data on analgesic effects of tegileridine in vivo (in rats) and in participants with moderateto-severe acute pain after abdominal surgery with an acceptable safety profile.  \n• This trial assessed tegileridine for moderate-to-severe acute postoperative pain  \n• Tegileridine was superior to placebo in analgesia and was comparable to morphine  \nWang et al., 2025, Cell Reports Medicine 6, 102477  \nDecember 16, 2025 © 2025 The Authors. Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2025.102477](https://doi.org/10.1016/j.xcrm.2025.102477)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nTegileridine for moderate-to-severe acute pain following abdominal surgery: A  \nrandomized, double-blind, phase 3 clinical trial  \nTingting Wang,1,2,3,22 Yafeng Wang,1,2,3,22 Haihui Xie,4,22 Zhilin Wu,1,2,3 Shuchun Yu,5 Yangwen Ou,6 Mingjun Xu,7 Wanwei Jiang,8 Liang Ge,9 Ju Gao,10 Qiang Wang,11 Hexin Gao,12 Yanjuan Huang,13 Ping Zhao,14 Yonghao Yu,15 He Huang,16 Jinghua Ren,17 Zhengyuan Xia,18,19 Jiaqiang Zhang,20,* Jianbo Yu,21,* and Xiangdong Chen1,2,3,23,*  \n1Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China  \n2Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China  \n3Key Laboratory of Anesthesiology and Resuscitation (Huazhong University of Science and Technology), Ministry of Education, Wuhan, China  \n4Department of Anesthesiology, Affiliated Dongguan People’s Hospital of Southern Medical University, Dongguan, Guangdong 523018, China  \n5Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, Nanchang 330000, China  \n6Department of Anesthesiology, The Third Xiangya Hospital, Central South University, Changsha 410013, China  \n7Department of Anaesthesiology, Beijing Obstetrics and Gynaecology Hospital, Capital Medical University, Beijing, China  \n8Department of Anesthesiology, The Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning Province 116001, China  \n9Department of Anesthesiology, The First Hospital, Jilin University, Changchun, China  \n10Department of Anesthesiology, Clinical Medical College of Yangzhou University (Northern Jiangsu People’s Hospital), Yangzhou 225001, China  \n11Department of Anesthesiology & Center for Brain Science, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China  \n12Department of Anesthesiology, Maternal and Child Health Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, Xinjiang, Uygur Autonomous Region, China  \n13Department of Anesthesiology, Nanning Second People’s Hospital, Nanning 530031, China  \n14Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, China  \n15Department of Anesthesiology, Tianjin Medical University General Hospital, Tianjin 300052, China  \n16Department of Anesthesiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China  \n17Department of Anesthesiology, The Second People’s Hospital of Yibin, Yibin, China  \n18State Key Laboratory of Pharmaceutical Biotechnology, Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China  \n19Department of Anesthesiology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China  \n20Department of Anesthesiology and Perioperative Medicine, Pe","cbCail8jJA4e5VCb","https://ap.wps.com/l/cbCail8jJA4e5VCb","pdf",2723677,13,"English","# Summary\n# Introduction\n# Trial Design and Outcomes\n## Primary outcome: SPID24\n## Secondary outcome: pain relief at 24 h\n# Overall Conclusion","[{\"question\":\"What medication and target does the trial evaluate?\",\"answer\":\"The trial evaluates tegileridine, a MOR-biased μ-opioid receptor agonist designed to provide analgesia with potentially fewer opioid-related adverse effects.\"},{\"question\":\"How were patients assigned in this phase 3 study?\",\"answer\":\"A total of 526 patients with postoperative pain after abdominal surgery were randomized to placebo, tegileridine (0.75 mg or 1.0 mg), or morphine under a randomized, double-blind design.\"},{\"question\":\"What did the primary outcome show compared with placebo and morphine?\",\"answer\":\"For the primary outcome of effective analgesia measured by SPID24 at rest over the first 24 hours, tegileridine produced significantly better pain reduction than placebo (all p\\u003c0.001) and was comparable to morphine.\"}]","Tegileridine for moderate-to-severe acute pain following abdominal surgery - A randomized, double-blind, phase 3 clinical trial | PDF",1790686868,33]